HIV/AIDS Drug Dangerous Side Effects

HIV/AIDS Drugs Sold Despite Known Dangerous Side Effects

If you have taken one or more of the HIV/AIDS drugs marketed as Viread, Truvada, Atripla, Complera, or Stribild, you may be at a needlessly high risk for permanent or fatal damage to your bones and kidneys.

You may also be a victim of pharmaceutical company misconduct and eligible for compensation for your injuries, but you must act quickly by calling Jenner Law at 410-413-2155 to learn your rights. This consultation is free.



Serious Side Effects Kept Secret

Evidence is mounting that Gilead Science, the sole maker of HIV/AIDS medications using a formulation known as tenofovir disoproxil fumarate (TDF), illegally withheld test results for more than a decade showing the drug formulation was highly dangerous. According to court documents, patients taking the tenofovir-based drugs developed the following serious medical complications in unusually high numbers:

  • Bone fractures
  • Chronic kidney disease (CKD) or declining kidney function
  • Acute kidney injury (AKI) or acute renal failure (ARF)

CALL US NOW AT 888-585-2188 FOR YOUR FREE CONSULTATION

We only handle cases on a contingency fee basis—we charge no fees or expenses unless there is a recovery in the case.

TDF Lawsuits Underway for Injured Patients

Lawsuits filed in several state and federal courts allege that Gilead Science knowingly injured patients by keeping alarming tenofovir disoproxil fumerate (TDF) test results secret, and by failing to warn doctors that a safer alternative existed. The lawsuits further allege Gilead Science developed and then intentionally delayed the market introduction of a safer HIV/AIDS treatment formulation known as tenofovir alafenamide fumarate (TAF), later marketed as the drugs Genvoya and Odefsey. The lawsuits claim that the motive behind the delay was to maximize profits from TDF drug sales (in the neighborhood of $11 billion annually) before patents on these drugs expired.

Urgent Action Required

Putting profits before the wellbeing of patients is immoral as well as illegal. If you have been diagnosed with bone loss or kidney damage after taking Viread, Truvada, Atripla, Complera, or Stribild, contact Jenner Law as soon as possible about your rights under the law.

Consultations are always free of charge and may lead to your being compensated by Gilead Science for related medical and other expenses. Family members of patients who may have died as a result of these complications also may be eligible for compensation.

Don’t delay. Call us now for free legal advice and for more information.

Jenner Law: 30+ Years Fighting Big Pharma

In October 2019, the Superior Court for the County of San Francisco appointed Rob Jenner as Co-Lead Counsel of the California coordination of the Gilead Tenofovir Cases -- Judicial Council Coordinated Proceeding No. 5043. As Co-Lead Counsel, he is charged with, among other responsibilities, facilitating, authorizing and directing the work of the Plaintiffs’ Executive Committee and Plaintiffs’ Steering Committee; and for managing on behalf of all Plaintiffs, the selection of cases for trial setting.

Rob Jenner has more than three decades experience as a leader in national lawsuits against major drug companies, and was an early courtroom advocate for better treatments for HIV and AIDS patients. He is the author of Transfusion-Associated AIDS, a legal treatise for lawyers handling AIDS related personal injury claims. He is the former Chair of the AIDS Litigation Group of the American Association for Justice, and has lectured internationally on the legal rights of persons impacted by HIV/AIDS. Mr. Jenner has been repeatedly selected by federal and state court judges to lead teams of plaintiffs’ attorneys in complicated, multi-district legal battles against some of the nation’s most powerful pharmaceutical and medical device companies. For the second year in a row, The National Trial Lawyers have named Rob Jenner one of America's Top 50 Influential Trial Lawyers. The announcement was made in The Trial Lawyer magazine (Spring 2019).